Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results

Atyr PHARMA (NASDAQ:ATYR) posted its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Stock Down 0.5 %

NASDAQ ATYR opened at $3.97 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.06. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a market capitalization of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Friday. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA presently has an average rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.